Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector

Oncotarget

Volumn 4, Issue 10, 2013, Pages 1829-1835

  Venanzi, Franco ^a   Shifrin, Victor ^b   Sherman, Michael Y ^c   Gabai, Vladimir ^b   Kiselev, Oleg ^d   Komissarov, Andrey ^d   Grudinin, Mikhail ^d   Shartukova, Maria ^d   Romanovskaya Romanko, Ekaterina A ^d   Kudryavets, Yuri ^e   Bezdenezhnykh, Natalya ^e   Lykhova, Oleksandra ^e   Semesyuk, Nadiia ^e   Concetti, Antonio ^a   Tsyb, Anatoly ^f   Filimonova, Marina ^f   Makarchuk, Victoria ^f   Yakubovsky, Raisa ^g   Chursov, Andrey ^b   Shcherbinina, Vita ^b   Shneider, Alexander ^b   more..

^a UNIVERSITY OF CAMERINO   (Italy)

^b Cure Lab   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Research Institute of Influenza   (Russian Federation)

^e R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^f MEDICAL RADIOLOGICAL RESEARCH CENTER   (Russian Federation)

^g P A Herzen Research Oncological Institute   (Russian Federation)

Author keywords

Autophagy; Cancer immunotherapy; DNA vaccine; Metastases

Indexed keywords

DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; P62 BASED DNA VACCINE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA; PROTEIN P62; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; LUNG METASTASIS; MALE; MELANOMA; MELANOMA B16; METASTASIS INHIBITION; MOUSE; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; SARCOMA; TUMOR VOLUME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BREAST NEOPLASMS; CARCINOMA, LEWIS LUNG; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; HUMANS; MALE; MAMMARY GLANDS, HUMAN; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; VACCINES, DNA;

EID: 84886732236     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1397     Document Type: Article

References (23)

1. Pardoll DM. Immunology beats cancer: a blueprint for successful translation. Nat Immunol. 2012; 13(12):1129-1132.
2. Denies S and Sanders NN. Recent progress in canine tumor vaccination: potential applications for human tumor vaccines. Expert Review of Vaccines. 2012; 11(11):1375-1386.
3. Guo K, Li J, Tang JP, Tan CP, Hong CW, Al-Aidaroos AQ, Varghese L, Huang C and Zeng Q. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med. 2011; 3(99):99ra85.
4. Guo K, Tang JP, Tan CP, Wang H and Zeng Q. Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice. Cancer Biol Ther. 2008; 7(5):750-757.
5. Zhu K, Qin H, Cha SC, Neelapu SS, Overwijk W, Lizee GA, Abbruzzese JL, Hwu P, Radvanyi L, Kwak LW and Chang DZ. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine. 2007; 25(46):7955-7961.
6. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, Leung L, Otten GR, Thudium K, Selby MJ and Ulmer JB. Increased DNA Vaccine Delivery and Immunogenicity by Electroporation In Vivo. The Journal of Immunology. 2000; 164(9):4635-4640.
7. Graham BS, Enama ME, Nason MC, Gordon IJ, Peel SA, Ledgerwood JE, Plummer SA, Mascola JR, Bailer RT, Roederer M, Koup RA, Nabel GJ and the VRCST. DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial. PLoS ONE. 2013; 8(4):e59340.
8. Ilyinskii PO, Meriin AB, Gabai VL, Zhirnov OP, Thoidis G and Shneider AM. Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response. Vaccine. 2008; 26(18):2177-2185.
9. Ilyinskii PO, Thoidis G, Sherman MY and Shneider A. Adjuvant potential of aggregate-forming polyglutamine domains. Vaccine. 2008; 26(26):3223-3226.
10. Diaz CM, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S, Fridman A, Fabregas J, Marshall J, Scarselli E, La Monica N, Ciliberto G and Montero A. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. Journal of Translational Medicine. 2013; 11(1):62.
11. Zhang H, Wang Y, Liu C, Zhang L, Xia Q, Zhang Y, Wu J, Jiang C, Chen Y, Wu Y, Zha X, Yu X and Kong W. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model. Cancer Immunology, Immunotherapy. 2012; 61(10):1857-1867.
12. Aleshin SE, Timofeev AV, Khoretonenko MV, Zakharova LG, Pashvykina GV, Stephenson JR, Shneider AM and Altstein AD. Combined prime-boost vaccination against tick-borne encephalitis (TBE) using a recombinant vaccinia virus and a bacterial plasmid both expressing TBE virus non-structural NS1 protein. BMC Microbiology. 2005; 5(1):45.
13. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MKK, Huang X, Caldwell S, Liu K, Smith P, Chen J-F, Jackson EK, Apasov S, Abrams S and Sitkovsky M. A2A adenosine receptor protects tumors from antitumor T cells. Proceedings of the National Academy of Sciences. 2006; 103(35):13132-13137.
14. Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-998.
15. Moscat J and Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell. 2009; 137(6):1001-1004.
16. Puissant A, Fenouille N and Auberger P. When autophagy meets cancer through p62/SQSTM1. Am J Cancer Res. 2012; 2(4):397-413.
17. Moscat J, Diaz-Meco MT and Wooten MW. Signal integration and diversification through the p62 scaffold protein. Trends Biochem Sci. 2007; 32(2):95-100.
18. Duran A, Linares JF, Galvez AS, Wikenheiser K, Flores JM, Diaz-Meco MT and Moscat J. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell. 2008; 13(4):343-354.
19. Kitamura H, Torigoe T, Asanuma H, Hisasue SI, Suzuki K, Tsukamoto T, Satoh M and Sato N. Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissue. Histopathology. 2006; 48(2):157-161.
20. Rolland P, Madjd Z, Durrant L, Ellis IO, Layfield R and Spendlove I. The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer. 2007; 14(1):73-80.
21. Thompson HG, Harris JW, Wold BJ, Lin F and Brody JP. p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells. Oncogene. 2003; 22(15):2322-2333.
22. Gabai VL, Yaglom JA, Waldman T and Sherman MY. Heat Shock Protein Hsp72 Controls Oncogene-Induced Senescence Pathways in Cancer Cells. 10.1128/ MCB.01041-08. Mol Cell Biol. 2009; 29(2):559-569.
23. Skivka LM, Trompak OO, Kudryavets YI, Bezdenezhnykh NA and Susak YM. The effect of NSC-631570 (ukrain) alone and in combination with pathogen-associated molecules on cell cycle distribution and apoptosis induction of mouse melanoma cells with different biological properties. Exp Oncol. 2010; 32(2):92-96.